kliovance
novo nordisk pharmaceuticals ltd - estradiol hemihydrate 1.03mg equivalent to 1 mg oestradiol; ; ; ; norethisterone acetate 0.5mg; ; ; - film coated tablet - active: estradiol hemihydrate 1.03mg equivalent to 1 mg oestradiol norethisterone acetate 0.5mg excipient: copovidone hypromellose lactose monohydrate magnesium stearate maize starch purified talc triacetin
trisequens (combination pack)
novo nordisk pharmaceuticals ltd - estradiol hemihydrate 2.07mg (adjustment for water content 3.2 %); ; ; ; norethisterone acetate 1mg; ; ; ; estradiol hemihydrate 1.03mg (adjustment for water content 3.2%); estradiol hemihydrate 2.07mg (adjustment for water content 3.2%); estradiol hemihydrate 2.07mg (adjustment for water content 3.2 %); estradiol hemihydrate 1.03mg (adjustment for water content 3.2 %); estradiol hemihydrate 2.07mg (adjustment for water content 3.2 %); norethisterone acetate 1mg - film coated tablet - active: estradiol hemihydrate 2.07mg (adjustment for water content 3.2 %) norethisterone acetate 1mg excipient: hyprolose hypromellose lactose monohydrate magnesium stearate maize starch purified talc purified water triacetin active: estradiol hemihydrate 1.03mg (adjustment for water content 3.2%) excipient: hyprolose hypromellose iron oxide red as red paste, with titanium dioxide, hypromellose, talc and propylene glycol lactose monohydrate magnesium stearate maize starch propylene glycol purified talc purified water titanium dioxide active: estradiol hemihydrate 2.07mg (adjustment for water content 3.2%) excipient: hyprolose hypromellose indigo carmine lactose monohydrate macrogol 400 magnesium stearate maize starch purified talc purified water titanium dioxide active: estradiol hemihydrate 2.07mg (adjustment for water content 3.2 %) estradiol hemihydrate 1.03mg (adjustment for water content 3.2 %) estradiol hemihydrate 2.07mg (adjustment for water content 3.2 %) norethisterone acetate 1mg - trisequens is indicated for the treatment of oestrogen deficiency syndrome, including prevention of bone mineral content loss in postmenopausal women at increased risk of developing fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis (see also warnings and precautions)
drospirenone/ ethinyloestradiol-gh tablets 3 mg/30 micrograms drospirenone/ethinylestradiol 3 mg/30 micrograms tablet blister pack
lupin australia pty limited - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive
drospirenone/ ethinyloestradiol-lupin tablets 3 mg/30 micrograms drospirenone/ethinylestradiol 3 mg/30 micrograms tablet blister
lupin australia pty limited - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 30 microgram - tablet - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive
brooke drospirenone/ethinyloestradiol 3 mg/20 microgram tablet blister composite pack
alphapharm pty ltd - ethinylestradiol, quantity: 0.02 mg; drospirenone, quantity: 3 mg - tablet - excipient ingredients: polacrilin potassium; magnesium stearate; lactose monohydrate - drospirenone/ethinyloestradiol-alphapharm 3/20 is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg/ethinyloestradiol 20 ?g tablets for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg/ethinyloestradiol 20 ?g tablets has not been evaluated for treatment of pms (premenstrual syndrome) (see clinical trials).
brooklynn drospirenone/ethinyloestradiol 3 mg/30 microgram tablet blister composite pack
alphapharm pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 0.03 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; polacrilin potassium - drospirenone/ethinyloestradiol-alphapharm 3/30 is indicated for use as an oral contraceptive.
postoval tablets
pharmacare limited - oestradiol valerate 2 mg (white), ; oestradiol valerate 2 mg and ; norgestrel 0.5 mg (orange) - tablet - oestradiol valerate 2 mg (white), ; oestradiol valerate 2 mg and ; norgestrel 0.5 mg (orange)
oestradiol benzoate 5 mg/ml solution for injection
intervet ireland limited - estradiol benzoate - solution for injection - 5 mg/ml - bovine - hormone
rwr tissue repair oily injection
rwr veterinary products pty ltd - nandrolone decanoate; oestradiol dipropionate; hydroxy progesterone hexanoate - parenteral liquid/solution/suspension - nandrolone decanoate steroid-anabolic active 80.0 mg/ml; oestradiol dipropionate steroid-estrogen active 1.3 mg/ml; hydroxy progesterone hexanoate steroid-progestin active 80.0 mg/ml - endocrine system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - anabolic steroid | abortion threat | androgenic properties | bone repair | catabolic complications | convalescence | erythropoietic activity | geriatric therapy | improve appetite | male sexual characterisitics | muscle development | non-virilising anabolic | pathophysiological process | protein and mineral anabolic | skeletal conditions | tissue breakdown | tissue repair | virilising anabolic
reepair anabolic steroid oily injection
jurox pty limited - nandrolone decanoate; oestradiol dipropionate; hydroxy progesterone hexanoate - parenteral liquid/solution/suspension - nandrolone decanoate steroid-anabolic active 80.0 mg/ml; oestradiol dipropionate steroid-estrogen active 2.0 mg/ml; hydroxy progesterone hexanoate steroid-progestin active 80.0 mg/ml - endocrine system - dog | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at - anabolic steroid | abortion threat | androgenic properties | bone repair | catabolic complications | convalescence | erythropoietic activity | geriatric therapy | improve appetite | male sexual characterisitics | muscle development | non-virilising anabolic | pathophysiological process | protein and mineral anabolic | skeletal conditions | tissue breakdown | tissue repair | virilising anabolic